Detection of antibodies to the hepatitis C virus using up-converting nanoparticles-based lateral flow immunoassay
Bayoumy, Sherif (2019-02-05)
Detection of antibodies to the hepatitis C virus using up-converting nanoparticles-based lateral flow immunoassay
(05.02.2019)
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
suljettu
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2019032710163
https://urn.fi/URN:NBN:fi-fe2019032710163
Tiivistelmä
Hepatitis C virus (HCV), an RNA virus, causes acute hepatitis and frequently causes chronic hepatitis, which can lead to liver cirrhosis and primary liver cancer. In 2015, the WHO reported that HCV infection globally affects 71 million persons, accounting for 1% of the population. Nonetheless, among them, only 20% (14 million) were diagnosed. The majority of HCV diagnostic tests are performed in large-scale centralized laboratories; the available tests need high operational costs and trained personnel. There is a pressing need for simple, affordable; quality assured HCV diagnostic test for decentralized and resource-constrained settings.
In order to develop the lateral flow immunoassay (LFIA) strips, a physical mixture of recombinant (r) HCV multiepitope protein (rHCV-MEP; containing peptides from structural and non-structural proteins of HCV) and rHCVNS3-core (a fusion of non-structural protein 3 (NS3) and core protein of HCV) was used as capture antigen on the test line of anti-HCV LFIA strips. Recombinant Protein-A conjugated to upconverting nanoparticles (UCNPs) was used as a tracer. The assay was optimized using the model analyte (anti-HCV-MEP rabbit serum) spiked in goat and human serum.
A reliable LFIA based on (UCNPs) as the label was developed for the qualitative detection of anti-HCV antibodies in human serum. The developed LFIA was evaluated with 50 anti-HCV positive and 50 anti-HCV negative human serum samples. The LFIA detected anti-HCV antibodies with a sensitivity of 92% (95% CI: 80.77% to 97.78%) and a specificity of 100% (95% CI: 92.89% to 100.00%). The assay could be optimized further to be used as a rapid point-of-care assay in the emergency units, physicians’ clinics, decentralized laboratories, and resource-constrained settings.
In order to develop the lateral flow immunoassay (LFIA) strips, a physical mixture of recombinant (r) HCV multiepitope protein (rHCV-MEP; containing peptides from structural and non-structural proteins of HCV) and rHCVNS3-core (a fusion of non-structural protein 3 (NS3) and core protein of HCV) was used as capture antigen on the test line of anti-HCV LFIA strips. Recombinant Protein-A conjugated to upconverting nanoparticles (UCNPs) was used as a tracer. The assay was optimized using the model analyte (anti-HCV-MEP rabbit serum) spiked in goat and human serum.
A reliable LFIA based on (UCNPs) as the label was developed for the qualitative detection of anti-HCV antibodies in human serum. The developed LFIA was evaluated with 50 anti-HCV positive and 50 anti-HCV negative human serum samples. The LFIA detected anti-HCV antibodies with a sensitivity of 92% (95% CI: 80.77% to 97.78%) and a specificity of 100% (95% CI: 92.89% to 100.00%). The assay could be optimized further to be used as a rapid point-of-care assay in the emergency units, physicians’ clinics, decentralized laboratories, and resource-constrained settings.